[1]马 明,谢华宁,张军茹.达格列净治疗2型糖尿病合并慢性心力衰竭临床疗效观察[J].陕西医学杂志,2021,50(1):93-95,99.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.025]
点击复制

达格列净治疗2型糖尿病合并慢性心力衰竭临床疗效观察
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
50
期数:
2021年1期
页码:
93-95,99
栏目:
药物与临床
出版日期:
2021-01-05

文章信息/Info

作者:
马 明; 谢华宁; 张军茹
(陕西省中医医院心内科,陕西 西安710003)
关键词:
达格列净;  钠-葡萄糖协同转运蛋白2抑制剂;  2型糖尿病;  慢性心力衰竭;  对比研究
分类号:
R 541.61
DOI:
DOI:10.3969/j.issn.1000-7377.2021.01.025
文献标志码:
A
摘要:
目的:探讨达格列净治疗2型糖尿病(T2DM)合并慢性心力衰竭(CHF)患者的临床疗效。方法:选取T2DM合并CHF患者134例,按是否服用达格列净分为研究组(66例)和对照组(68例)。对照组治疗包括生活方式干预及标准治疗,研究组治疗包括生活方式干预及标准治疗,但T2DM治疗采用达格列净。治疗1年后,观察两组尿酸(UA)、糖化血红蛋白(HbA1c)、血压、氨基末端脑钠肽前体(NT-proBNP)、6 min步行距离、左心室射血分数(LVEF)和左心室舒张末期内径(LVEDd)的变化,以及再住院和不良反应发生情况。结果:治疗前,对照组和治疗组UA、HbA1c、NT-proBNP、LVEDd、LVEF、收缩压(SBP)、舒张压(DBP)以及6 min步行距离比较,差异无统计学意义(P>0.05)。治疗后,两组HbA1c、UA、NT-proBNP、SBP、DBP、LVEDd均低于治疗前,6 min步行距离、LVEF则较治疗前增加,差异均具有统计学意义(P<0.05)。同时,治疗后研究组HbA1c、UA、NT-proBNP、SBP、DBP均低于对照组,6 min步行距离高于对照组,差异均有统计学意义(P<0.05)。研究组再住院率低于对照组(P< 0.05),但两组不良反应发生率比较无统计学差异(P>0.05)。结论:达格列净治疗T2DM合并CHF能改善患者症状和预后。

参考文献/References:

[1] 凌 望,孙思明,王璐玲,等.温阳益气活血方改善慢性心力衰竭患者生活质量临床研究[J].陕西中医,2020,41(5):621-624.
[2] 彭艳玲,王冉冉,黄 洁,等.左西孟旦治疗慢性心力衰竭的疗效分析[J].中国急救复苏与灾害医学杂志,2018,13(6):533-535.
[3] Nikolic S,Dugic A,Steiner C,et al.Chronic pancreatitis and the heart disease:still terra incognita?[J].World J Gastroenterology,2019,25(44):6561-6570.
[4] Liu B,Li Y,Liu J,et al.Assessing inflammation in Chinese subjects with subtypes of heart failure:an observational study of the Chinese PLA Hospital Heart Failure Registry[J].J Geriatric Cardiology,2019,16(4):313-319.
[5] Nassif ME,Windsor SL,Tang F,et al.Dapagliflozin effects on biomarkers,symptoms,and functional status in patients with heart failure with reduced ejection fraction:the DEFINE-HF trial[J].Circulation,2019,140(18):1463-1476.
[6] Sandesara PB,O'Neal WT,Kelli HM,et al.The prognostic significance of diabetes and microvascular complications in patients with heart failure with preserved ejection fraction[J].Diabetes Care,2018,41(1):150-155.
[7] Yancy CW,Jessup M,Bozkurt B,et al.2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J].Journal of the American College of Cardiology,2013,62(16):e147-e239.
[8] Zinman B,Wanner C,Lachin JM,et al.Empagliflozin,cardiovascular outcomes,and mortality in type 2 diabetes[J].New England J Medicine,2015,373(22):2117-2128.
[9] Arnolds SV,Echouffo-Tcheugui JB,Lam CSP,et al.Patterns of glucose-lowering medication use in patients with type-2 diabetes and heart failure,insights from the Diabetes Collaborative Registry(DCR)[J].Am Heart J,2018,203:25-29.
[10] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中华糖尿病杂志,2018,10(1):4-67.
[11] 王 华,梁延春.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
[12] Raz I,Mosenzon O,Bonaca MP,et al.Declare-TIMI58:participants' baseline characteristics[J].Diabetes Obesity & Metabolism,2018,20(5):1102-1110.
[13] Zelniker TA,Wiviott SD,Raz I,et al.SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes:a systematic review and meta-analysis of cardiovascular outcomes trials[J].Lancet,2019,393(10166):31-39.
[14] 司道远,杨 萍.2018 ESC心力衰竭协会2型糖尿病和心力衰竭立场声明解读[J].中国循环杂志,2018,33(S2):55-58.
[15] Knuuti J,Wijns W,Saraste A,et al.2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes:the task force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology(ESC)[J].European Heart Journal,2020,54(3):407-477.
[16] Filion KB,Azoulay L,Piatt RW,et al.A multicenter observational study of incretin-based drugs and heart failure[J].New England J Medicine,2016,374(12):1145-1154.
[17] Mac Donald MR,Petrie MC,Hawkins NM,et al.Diabetes,left ventricular systolic dysfunction,and chronic heart failure[J].European Heart J,2008,29(10):1224-1240.
[18] Cosentino F,Grant PJ,Aboyans V,et al.2019 ESC guidelines on diabetes,pre-diabetes,and cardiovascular diseases developed in collaboration with the EASD:the task force for diabetes,pre-diabetes,and cardiovascular diseases of the European Society of Cardiology(ESC)and the European Association for the Study of Diabetes(EASD)[J].European Heart J,2020,41(2):255-323.
[19] Gambassi G,Cesari M,Tosato M,et al.Just 6 minutes to get to the heart of frailty:the walking test in geriatric cardiology[J].Giornaleitaliano Dicardiologia(2006),2013,14(3):19-25.
[20] Kaplinsky E.DAPA-HF trial:dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure[J].Drugs Context,2020,9:1-7.
[21] Dhillon S.Dapagliflozin:a review in type 2 diabetes drugs[J].Drugs,2019,79(10):1135-1146.
[22] Kato ET,Silverman MG,Mosenzon O,et al.Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus[J].Circulation,2019,139(22):2528-2536.
[23] 武卫党,石 磊,张丹凤,等.达格列净对糖尿病心肌缺血大鼠心肌功能改善作用的实验研究[J].陕西医学杂志,2020,49(7):778-780.
[24] Jonnalagadda VG,Choudhary K,Matety VK.Sodium glucose cotransporter-2 inhibitors:are we targeting old devil with new problems?[J].Asian Pacific Journal of Tropical Biomedicine,2017,7(11):1032-1034.
[25] Cho YK,Kang YM,Lee SE,et al.Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes:a systematic review and meta-analysis[J].Diabetes and Metabolism,2018,44(5):393-401.
[26] Ribola FA,Cancado FB,Schoueri JHM,et al.Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus[J].European Review for Medical and Pharmacological Sciences,2017,21(1):199-211.
[27] Baartscheer A,Schumacher CA,Wüst RCI,et al.Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits[J].Diabetologia,2017,60(3):568-573.

相似文献/References:

[1]武卫党,石 磊,张丹凤△,等.达格列净对糖尿病心肌缺血大鼠心肌功能改善作用的实验研究*[J].陕西医学杂志,2020,49(7):778.[doi:DOI:10.3969/j.issn.10007377.2020.07.003]
[2]梁 蒙,杨 雀,陈伟国,等.达格列净联合阿托伐他汀治疗糖尿病心肌病疗效及对患者Klotho和心室重构的影响[J].陕西医学杂志,2023,52(7):898.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.028]
　LIANG Meng,YANG Que,CHEN Weiguo,et al.Efficacy of dapagliflozin combined with atorvastatin in treatment of diabetes cardiomyopathy and effects on Klotho and ventricular remodeling in patients[J].,2023,52(1):898.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.028]

备注/Memo

备注/Memo:
基金项目:陕西省重点研发计划项目(2018SF-346)
更新日期/Last Update: 2021-01-05